At Bristows, we have been involved in the biotech sector since the earliest days of its emergence, representing Genentech and Chiron Corporation during the 1980s and 1990s in two of the UK’s highest profile biotech patent cases.
We have stayed close to the industry throughout the years, advising on a wide range of legal issues from patent protection, enforcement and freedom to operate, navigation of the regulatory regime for complex new products, spin-outs, financings, IPOs and other exits as well as the full range of transactions relating to the development and commercialisation of biotech products. We have advised on the application of competition law to developing business models and handled a number of complex arbitrations in this area.
We have been deeply involved in developments surrounding antibody technology and, more recently, cell and gene therapies and the business opportunities afforded, including advising on the exploitation of immunotherapy, gene therapy and gene editing technologies. This has been coupled with expertise in the legal issues surrounding gene sequencing and the exploitation of data.